Exhibit 99.1

1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com

News Release

Contact:
Zachary A. Nagle, Investor Relations — 201-847-5453
Colleen T. White, Corporate Communications — 201-847-5369

BD ANNOUNCES RESULTS FOR 2010 FOURTH FISCAL QUARTER AND FULL YEAR

	•		Reports diluted earnings per share from continuing operations of $1.24 for the fourth quarter and $4.90 for the full fiscal year, in line with the Company’s expectations.
	•		States that reported earnings reflect the reclassification of the operating results and gain on the sale of the Ophthalmic Systems unit and certain platforms of the Medical Surgical Systems unit as discontinued operations.
	•		Announces planned stock repurchases of $1.5 billion in 2011 funded by ongoing cash flow and the issuance of debt.
	•		Expects full fiscal year 2011 diluted earnings per share from continuing operations to be between $5.45 and $5.55, an increase of 11 to 13 percent on an as-reported basis.

Franklin Lakes, NJ (November 3, 2010) — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.873 billion for the fourth fiscal quarter ended September 30, 2010, representing an increase of 1.0 percent from the prior-year period, or 2.9 percent on a foreign currency-neutral basis.

For the full fiscal year ended September 30, 2010, BD reported revenues of $7.372 billion, representing an increase of 5.5 percent over the prior year, or 5.6 percent on a foreign currency-neutral basis.

The Company also plans to repurchase $1.5 billion of its common stock in 2011 and an additional $600 million in 2012. The Company plans to fund the repurchases through ongoing cash flow and the issuance of debt.

“We are proud of our accomplishments during 2010. We met our financial and operational goals despite the challenging macroeconomic climate facing our industry,” said Edward J. Ludwig, Chairman and Chief Executive Officer. “Our solid performance has enabled us to continue to return significant value to shareholders and also to invest in key geographic expansion, new product platforms and businesses and operational excellence programs. We have confidence in our outlook for fiscal year 2011 and remain committed to serving our customers with superior healthcare products.”

Update on the Sale of Certain Assets in the BD Medical Segment

In the fourth quarter of fiscal year 2010, the Company completed the sale of the Ophthalmic Systems unit as well as the surgical blades, critical care and extended dwell catheter product platforms. The results of operations associated with the Ophthalmic Systems unit, surgical blade platform and critical care platform have been reclassified as discontinued operations for all quarters and years referred to in this release.

As illustrated on page 3 of the attached financial tables, diluted earnings per share from discontinued operations for the fourth quarter of $0.44 consisted of $0.06 from operations and $0.39 from the gain on the sale. Diluted earnings per share for the fourth quarter of $1.68 less the $0.44 from discontinued operations resulted in diluted earnings per share from continuing operations of $1.24. Diluted earnings per share from discontinued operations for the year of $0.59 consisted of $0.21 from operations and $0.38 from the gain on the sale. Diluted earnings per share for the year of $5.49 less the $0.59 from discontinued operations resulted in diluted earnings per share from continuing operations of $4.90.

Also included in the attached financial tables are the Company’s Consolidated Income Statements for the first three quarters of fiscal year 2010 and for all periods in fiscal year 2009 for reference, which reflect the reclassification change for the Ophthalmic Systems unit, surgical blade platform and critical care platform. The results of operations associated with the extended dwell catheter product platform are reported within continuing operations, as this asset group did not meet the criteria for discontinued operations.

Fourth Quarter Earnings and Analysis of the Full Fiscal Year 2010 and 2009 Earnings

Reported diluted earnings per share from continuing operations for the fourth quarter were $1.24, compared with $1.20 in the prior-year period, representing a 3.3 percent increase. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fourth quarter increased by 1.7 percent.

For the full fiscal year ended September 30, 2010, reported diluted earnings per share from continuing operations were $4.90, compared with $4.73 in the prior fiscal year, representing an increase of 3.6 percent. Current full fiscal year results include a previously disclosed non-cash charge of $8.9 million, or $0.04 per share from continuing operations, related to healthcare reform impacting Medicare Part D reimbursements. The prior fiscal year included a $20 million, or $0.08 per share, tax benefit related to various tax settlements in multiple jurisdictions and a litigation charge of $45 million, or $0.11 per share, which were also previously disclosed. Excluding these items, adjusted diluted earnings per share from continuing operations increased by 3.8 percent to $4.94, compared with $4.76 adjusted diluted earnings per share in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fiscal year increased 9.2 percent.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $959 million, representing a decrease of 0.3 percent compared with the prior-year period. Revenues increased 2.1 percent on a foreign currency-neutral basis. Segment revenue growth reflected an unfavorable comparison to the prior year of 4.3 percentage points due to the sales related to the H1N1 flu pandemic in fiscal year 2009, partially offset by strong growth in the Diabetes Care business. For the twelve-month period ended September 30, 2010, BD Medical revenues increased 6.7 percent, or 6.2 percent on a foreign currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were $591 million, representing an increase of 2.0 percent compared with the prior-year period, or 3.1 percent on a foreign currency-neutral basis. Segment revenue growth was negatively impacted by 2.4 percentage points due to sales

related to the flu pandemic in fiscal year 2009 in addition to lower lab testing and reduced physician office visits. For the twelve-month period ended September 30, 2010, BD Diagnostics revenues increased 4.2 percent, or 4.0 percent on a foreign currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were $323 million, representing an increase of 3.5 percent compared with the prior-year period. Revenues increased 5.3 percent on a foreign currency-neutral basis, primarily driven by instrument and reagent sales in the Cell Analysis business unit. For the twelve-month period ended September 30, 2010, BD Biosciences revenues increased 4.4 percent, or 6.8 percent on a foreign currency-neutral basis.

Geographic Results

Fourth quarter revenues in the U.S. were $832 million, representing an increase of 1.4 percent compared with the prior-year period, including a negative impact of 1.8 percentage points related to the flu pandemic. Revenues outside of the U.S. were $1.041 billion, representing an increase of 0.8 percent compared with the prior-year period, or 4.2 percent on a foreign currency-neutral basis. International revenue growth was negatively impacted by 4 percentage points due to the H1N1 flu pandemic-related sales in fiscal year 2009. Revenues reflected continuing strength in emerging markets, which was partially offset by slower growth in Europe. For the twelve-month period ended September 30, 2010, revenues in the U.S. were $3.287 billion, representing an increase of 5.0 percent compared with the prior-year period. Revenues outside of the U.S. were $4.086 billion, representing an increase of 5.9 percent compared with the prior-year period, or 6.0 percent on a foreign currency-neutral basis.

Fiscal 2011 Outlook for Full Year

The Company estimates that reported revenues for the full fiscal year 2011 will increase about 4 percent. The Company also expects reported diluted earnings per share from continuing operations for fiscal year 2011 to be between $5.45 and $5.55, an increase of approximately 11 to 13 percent over fiscal year 2010. Diluted earnings per share from continuing operations for fiscal year 2011 are expected to increase 10 to 12 percent over adjusted diluted earnings per share from continuing operations, excluding specified item, of $4.94 for the fiscal year 2010.

Conference Call Information

A conference call regarding BD’s fourth quarter results and its expectations for the full fiscal year 2011 will be broadcast live on BD’s website, www.bd.com/investors, along with related slides, at 10:00 a.m. (ET) Thursday, November 4, 2010. The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 1-800-642-1687 (domestic) and 1-706-645-9291 (international) through the close of business on Thursday, November 11, 2010, access code 15660232.

Non-GAAP Financial Measures

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables and the Form 8-K that BD filed today with the SEC.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of

diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

***

This press release, including the section entitled “Fiscal 2011 Outlook”, contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: the unknown consequences of the recently-enacted healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic downturn on our ability to access credit markets and finance our operations, the demand for our products and services, or our suppliers’ ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; our ability to successfully integrate any businesses we acquire; and issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

		Three Months Ended September 30,
		2010				2009				% Change
REVENUES		$	1,873,195			$	1,854,023				1.0
Cost of products sold			900,933				890,197				1.2
Selling and administrative			438,139				427,008				2.6
Research and development			123,606				112,890				9.5
TOTAL OPERATING COSTS AND EXPENSES			1,462,678				1,430,095				2.3
OPERATING INCOME			410,517				423,928				(3.2	)
Interest income			14,594				14,418				1.2
Interest expense			(12,278	)			(13,782	)			(10.9	)
Other income (expense), net			1,285				(3,312	)		NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES			414,118				421,252				(1.7	)
Income tax provision			121,065				126,824				(4.5	)
INCOME FROM CONTINUING OPERATIONS			293,053				294,428				(0.5	)
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF $27,645 AND $7,684, RESPECTIVELY			103,642				22,792			NM
NET INCOME		$	396,695			$	317,220				25.1
EARNINGS PER SHARE
Basic:
Income from continuing operations		$	1.27			$	1.23				3.3
Income from discontinued operations		$	0.45			$	0.10			NM
Net income (1)		$	1.71			$	1.33				28.6
Diluted:
Income from continuing operations		$	1.24			$	1.20				3.3
Income from discontinued operations		$	0.44			$	0.09			NM
Net income		$	1.68			$	1.29				30.2
AVERAGE SHARES OUTSTANDING
Basic			231,396				239,162
Diluted			236,316				245,056

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

		Twelve Months Ended September 30,
		2010				2009				% Change
REVENUES		$	7,372,333			$	6,986,722				5.5
Cost of products sold			3,543,183				3,311,676				7.0
Selling and administrative			1,721,356				1,680,797				2.4
Research and development			430,997				404,567				6.5
TOTAL OPERATING COSTS AND EXPENSES			5,695,536				5,397,040				5.5
OPERATING INCOME			1,676,797				1,589,682				5.5
Interest income			35,129				33,148				6.0
Interest expense			(51,263	)			(40,389	)			26.9
Other income (expense), net			497				(3,850	)		NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES			1,661,160				1,578,591				5.2
Income tax provision			484,820				411,246				17.9
INCOME FROM CONTINUING OPERATIONS			1,176,340				1,167,345				0.8
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF $40,703 AND $19,975, RESPECTIVELY			141,270				64,258			NM
NET INCOME		$	1,317,610			$	1,231,603				7.0
EARNINGS PER SHARE
Basic:
Income from continuing operations		$	5.02			$	4.85				3.5
Income from discontinued operations		$	0.60			$	0.27			NM
Net income		$	5.62			$	5.12				9.8
Diluted:
Income from continuing operations		$	4.90			$	4.73				3.6
Income from discontinued operations		$	0.59			$	0.26			NM
Net income		$	5.49			$	4.99				10.0
AVERAGE SHARES OUTSTANDING
Basic			234,328				240,479
Diluted			240,136				246,798

Becton Dickinson and Company
Supplemental Income Statement Information — Fiscal 2010
Revised for discontinued operations of certain Medical segment divestitures
(Unaudited: Amounts in thousands, except per-share data)

						Amounts
						Reclassified
		Previously				to Discontinued				As
		Reported				Operations				Revised
Quarter 1
Revenues		$	1,916,774			$	47,956			$	1,868,818
Income from Continuing Operations		$	315,978			$	11,885			$	304,093
Diluted Earnings Per Share from Continuing Operations		$	1.30			$	0.05			$	1.25
Quarter 2
Revenues		$	1,844,854			$	45,445			$	1,799,409
Income from Continuing Operations		$	297,725			$	12,691			$	285,034
Diluted Earnings Per Share from Continuing Operations (2)		$	1.24			$	0.05			$	1.18
Quarter 3
Revenues		$	1,878,229			$	47,318			$	1,830,911
Income from Continuing Operations		$	306,283			$	12,123			$	294,160
Diluted Earnings Per Share from Continuing Operations (2)		$	1.29			$	0.05			$	1.23

						Amounts Reclassified to
						Discontinued Operations												From
						Operations				Gain								Continuing
		Total				Excluding Gain				on Sale				Total				Operations
Quarter 4 (1)
Revenues		$	1,899,548			$	26,353			$	—			$	26,353			$	1,873,195
Income		$	397,445			$	13,258			$	91,134			$	104,392			$	293,053
Diluted Earnings Per Share (2)		$	1.68			$	0.06			$	0.39			$	0.44			$	1.24
Year (1)
Revenues		$	7,539,405			$	167,072			$	—			$	167,072			$	7,372,333
Income		$	1,317,431			$	49,957			$	91,134			$	141,091			$	1,176,340
Diluted Earnings Per Share		$	5.49			$	0.21			$	0.38			$	0.59			$	4.90

Becton Dickinson and Company
Supplemental Income Statement Information — Fiscal 2009 and 2008
Revised for discontinued operations of certain Medical segment divestitures
(Unaudited: Amounts in thousands, except per-share data)

						Amounts
						Reclassified
		Previously				to Discontinued				As
		Reported				Operations				Revised
Fiscal 2009
Revenues		$	7,160,874			$	174,152			$	6,986,722
Income from Continuing Operations		$	1,213,054			$	45,709			$	1,167,345
Diluted Earnings Per Share from Continuing Operations		$	4.92			$	0.19			$	4.73
Fiscal 2008
Revenues		$	7,074,942			$	177,323			$	6,897,619
Income from Continuing Operations		$	1,115,867			$	38,113			$	1,077,754
Diluted Earnings Per Share from Continuing Operations		$	4.42			$	0.15			$	4.27

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

		Three Months Ended September 30,
		2010				2009				% Change
BD MEDICAL
United States		$	400,231			$	392,111				2.1
International			558,374				569,677				(2.0	)
TOTAL		$	958,605			$	961,788				(0.3	)
BD DIAGNOSTICS
United States		$	307,721			$	305,488				0.7
International			283,743				274,521				3.4
TOTAL		$	591,464			$	580,009				2.0
BD BIOSCIENCES
United States		$	124,009			$	123,225				0.6
International			199,117				189,001				5.4
TOTAL		$	323,126			$	312,226				3.5
TOTAL REVENUES
United States		$	831,961			$	820,824				1.4
International			1,041,234				1,033,199				0.8
TOTAL		$	1,873,195			$	1,854,023				1.0

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

		Twelve Months Ended September 30,
		2010				2009				% Change
BD MEDICAL
United States		$	1,596,336			$	1,503,471				6.2
International			2,200,096				2,053,223				7.2
TOTAL		$	3,796,432			$	3,556,694				6.7
BD DIAGNOSTICS
United States		$	1,214,288			$	1,177,543				3.1
International			1,104,591				1,048,676				5.3
TOTAL		$	2,318,879			$	2,226,219				4.2
BD BIOSCIENCES
United States		$	475,941			$	449,151				6.0
International			781,081				754,658				3.5
TOTAL		$	1,257,022			$	1,203,809				4.4
TOTAL REVENUES
United States		$	3,286,565			$	3,130,165				5.0
International			4,085,768				3,856,557				5.9
TOTAL		$	7,372,333			$	6,986,722				5.5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30,
(Unaudited; Amounts in thousands)

		United States
		2010				2009				% Change
BD MEDICAL
Medical Surgical Systems		$	256,290			$	255,168				0.4
Diabetes Care			98,633				88,590				11.3
Pharmaceutical Systems			45,308				48,353				(6.3	)
TOTAL		$	400,231			$	392,111				2.1
BD DIAGNOSTICS
Preanalytical Systems		$	162,024			$	156,328				3.6
Diagnostic Systems			145,697				149,160				(2.3	)
TOTAL		$	307,721			$	305,488				0.7
BD BIOSCIENCES
Cell Analysis		$	86,765			$	84,179				3.1
Discovery Labware			37,244				39,046				(4.6	)
TOTAL		$	124,009			$	123,225				0.6
TOTAL UNITED STATES		$	831,961			$	820,824				1.4

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

		International
										% Change
		2010				2009				Reported				FXN				FX Impact
BD MEDICAL
Medical Surgical Systems		$	245,724			$	253,384				(3.0	)			(2.2	)			(0.8	)
Diabetes Care			100,468				92,098				9.1				12.0				(2.9	)
Pharmaceutical Systems			212,182				224,195				(5.4	)			2.8				(8.2	)
TOTAL		$	558,374			$	569,677				(2.0	)			2.1				(4.1	)
BD DIAGNOSTICS
Preanalytical Systems		$	144,421			$	138,297				4.4				7.4				(3.0	)
Diagnostic Systems			139,322				136,224				2.3				4.1				(1.8	)
TOTAL		$	283,743			$	274,521				3.4				5.7				(2.3	)
BD BIOSCIENCES
Cell Analysis		$	160,230			$	150,055				6.8				10.4				(3.6	)
Discovery Labware			38,887				38,946				(0.2	)			0.8				(1.0	)
TOTAL		$	199,117			$	189,001				5.4				8.4				(3.0	)
TOTAL INTERNATIONAL		$	1,041,234			$	1,033,199				0.8				4.2				(3.4	)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

		Total
										% Change
		2010				2009				Reported				FXN				FX Impact
BD MEDICAL
Medical Surgical Systems		$	502,014			$	508,552				(1.3	)			(0.9	)			(0.4	)
Diabetes Care			199,101				180,688				10.2				11.7				(1.5	)
Pharmaceutical Systems			257,490				272,548				(5.5	)			1.2				(6.7	)
TOTAL		$	958,605			$	961,788				(0.3	)			2.1				(2.4	)
BD DIAGNOSTICS
Preanalytical Systems		$	306,445			$	294,625				4.0				5.4				(1.4	)
Diagnostic Systems			285,019				285,384				(0.1	)			0.7				(0.8	)
TOTAL		$	591,464			$	580,009				2.0				3.1				(1.1	)
BD BIOSCIENCES
Cell Analysis		$	246,995			$	234,234				5.4				7.8				(2.4	)
Discovery Labware			76,131				77,992				(2.4	)			(1.9	)			(0.5	)
TOTAL		$	323,126			$	312,226				3.5				5.3				(1.8	)
TOTAL REVENUES		$	1,873,195			$	1,854,023				1.0				2.9				(1.9	)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30,
(Unaudited; Amounts in thousands)

		United States
		2010				2009				% Change
BD MEDICAL
Medical Surgical Systems		$	1,007,322			$	974,324				3.4
Diabetes Care			383,783				351,618				9.1
Pharmaceutical Systems			205,231				177,529				15.6
TOTAL		$	1,596,336			$	1,503,471				6.2
BD DIAGNOSTICS
Preanalytical Systems		$	627,421			$	608,754				3.1
Diagnostic Systems			586,867				568,789				3.2
TOTAL		$	1,214,288			$	1,177,543				3.1
BD BIOSCIENCES
Cell Analysis		$	326,916			$	303,846				7.6
Discovery Labware			149,025				145,305				2.6
TOTAL		$	475,941			$	449,151				6.0
TOTAL UNITED STATES		$	3,286,565			$	3,130,165				5.0

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

		International
										% Change
		2010				2009				Reported				FXN				FX Impact
BD MEDICAL
Medical Surgical Systems		$	1,002,687			$	914,990				9.6				6.6				3.0
Diabetes Care			401,976				363,319				10.6				9.1				1.5
Pharmaceutical Systems			795,433				774,914				2.6				4.3				(1.7	)
TOTAL		$	2,200,096			$	2,053,223				7.2				6.2				1.0
BD DIAGNOSTICS
Preanalytical Systems		$	570,386			$	534,677				6.7				5.8				0.9
Diagnostic Systems			534,205				513,999				3.9				3.9				—
TOTAL		$	1,104,591			$	1,048,676				5.3				4.9				0.4
BD BIOSCIENCES
Cell Analysis		$	624,322			$	600,671				3.9				7.9				(4.0	)
Discovery Labware			156,759				153,987				1.8				4.5				(2.7	)
TOTAL		$	781,081			$	754,658				3.5				7.2				(3.7	)
TOTAL INTERNATIONAL		$	4,085,768			$	3,856,557				5.9				6.0				(0.1	)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

		Total
										% Change
		2010				2009				Reported				FXN				FX Impact
BD MEDICAL
Medical Surgical Systems		$	2,010,009			$	1,889,314				6.4				4.9				1.5
Diabetes Care			785,759				714,937				9.9				9.1				0.8
Pharmaceutical Systems			1,000,664				952,443				5.1				6.4				(1.3	)
TOTAL		$	3,796,432			$	3,556,694				6.7				6.2				0.5
BD DIAGNOSTICS
Preanalytical Systems		$	1,197,807			$	1,143,431				4.8				4.4				0.4
Diagnostic Systems			1,121,072				1,082,788				3.5				3.5				—
TOTAL		$	2,318,879			$	2,226,219				4.2				4.0				0.2
BD BIOSCIENCES
Cell Analysis		$	951,238			$	904,517				5.2				7.8				(2.6	)
Discovery Labware			305,784				299,292				2.2				3.6				(1.4	)
TOTAL		$	1,257,022			$	1,203,809				4.4				6.8				(2.4	)
TOTAL REVENUES		$	7,372,333			$	6,986,722				5.5				5.6				(0.1	)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
SAFETY REVENUES
(Unaudited; Amounts in thousands)

		Three Months Ended September 30,
										% Change
		2010				2009				Reported				FXN				FX Impact
TOTAL SAFETY REVENUES
United States		$	282,968			$	276,409				2.4				2.4				—
International			160,396				150,270				6.7				9.2				(2.5	)
TOTAL		$	443,364			$	426,679				3.9				4.8				(0.9	)
BY SEGMENT
BD Medical		$	208,822			$	204,536				2.1				2.7				(0.6	)
BD Diagnostics			234,542				222,143				5.6				6.7				(1.1	)
TOTAL		$	443,364			$	426,679				3.9				4.8				(0.9	)

		Twelve Months Ended September 30,
										% Change
		2010				2009				Reported				FXN				FX Impact
TOTAL SAFETY REVENUES
United States		$	1,108,431			$	1,056,797				4.9				4.9				—
International			621,913				568,106				9.5				8.1				1.4
TOTAL		$	1,730,344			$	1,624,903				6.5				6.0				0.5
BY SEGMENT
BD Medical		$	819,084			$	761,262				7.6				6.9				0.7
BD Diagnostics			911,260				863,641				5.5				5.2				0.3
TOTAL		$	1,730,344			$	1,624,903				6.5				6.0				0.5

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS FISCAL 2010
Revised for discontinued operations of certain Medical segment divestitures
(Unaudited; Amounts in thousands, except per-share data)

		Quarter 1				Quarter 2				Quarter 3				Quarter 3 YTD
REVENUES		$	1,868,818			$	1,799,409			$	1,830,911			$	5,499,138
Cost of products sold			894,324				864,492				883,434				2,642,250
Selling and administrative			445,673				421,076				416,468				1,283,217
Research and development			99,151				100,193				108,047				307,391
TOTAL OPERATING COSTS AND EXPENSES			1,439,148				1,385,761				1,407,949				4,232,858
OPERATING INCOME			429,670				413,648				422,962				1,266,280
Interest income			8,789				9,652				2,094				20,535
Interest expense			(12,987	)			(12,913	)			(13,085	)			(38,985	)
Other (expense) income, net			(2,354	)			164				1,402				(788	)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES			423,118				410,551				413,373				1,247,042
Income tax provision			119,025				125,517				119,213				363,755
INCOME FROM CONTINUING OPERATIONS			304,093				285,034				294,160				883,287
Income from Discontinued Operations before Income Tax			16,900				16,698				17,088				50,686
Income Tax provision			4,617				4,101				4,340				13,058
INCOME FROM DISCONTINUED OPERATIONS			12,283				12,597				12,748				37,628
NET INCOME		$	316,376			$	297,631			$	306,908				920,915
EARNINGS PER SHARE
Basic:
Income from continuing operations		$	1.28			$	1.21			$	1.26			$	3.75
Income from discontinued operations		$	0.05			$	0.05			$	0.05			$	0.16
Net income (1)		$	1.33			$	1.26			$	1.32			$	3.91
Diluted:
Income from continuing operations		$	1.25			$	1.18			$	1.23			$	3.66
Income from discontinued operations		$	0.05			$	0.05			$	0.05			$	0.16
Net income (1)		$	1.30			$	1.24			$	1.29			$	3.82
AVERAGE SHARES OUTSTANDING
Basic			237,360				235,325				233,242				235,316
Diluted			242,965				240,863				238,319				241,151

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS FISCAL 2009
Revised for discontinued operations of certain Medical segment divestitures
(Unaudited; Amounts in thousands, except per-share data)

		Quarter 1				Quarter 2				Quarter 3				Quarter 4				Year
REVENUES		$	1,673,148			$	1,683,142			$	1,776,409			$	1,854,023			$	6,986,722
Cost of products sold			775,542				807,382				838,555				890,197				3,311,676
Selling and administrative			399,668				430,608				423,513				427,008				1,680,797
Research and development			96,356				97,700				97,621				112,890				404,567
TOTAL OPERATING COSTS AND EXPENSES			1,271,566				1,335,690				1,359,689				1,430,095				5,397,040
OPERATING INCOME			401,582				347,452				416,720				423,928				1,589,682
Interest income			1,651				4,312				12,767				14,418				33,148
Interest expense			(7,824	)			(7,495	)			(11,288	)			(13,782	)			(40,389	)
Other income (expense), net			9,411				(5,701	)			(4,246	)			(3,312	)			(3,850	)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES			404,820				338,568				413,953				421,252				1,578,591
Income tax provision			108,213				89,702				86,508				126,824				411,246
INCOME FROM CONTINUING OPERATIONS			296,607				248,866				327,445				294,428				1,167,345
Income from Discontinued Operations before Income Tax			20,234				15,944				17,579				30,476				84,233
Income Tax provision			4,773				3,521				3,997				7,684				19,975
INCOME FROM DISCONTINUED OPERATIONS			15,461				12,423				13,582				22,792				64,258
NET INCOME		$	312,068			$	261,289			$	341,027			$	317,220			$	1,231,603
EARNINGS PER SHARE
Basic:
Income from continuing operations		$	1.22			$	1.04			$	1.36			$	1.23			$	4.85
Income from discontinued operations		$	0.06			$	0.05			$	0.06			$	0.10			$	0.27
Net income (1)		$	1.29			$	1.09			$	1.42			$	1.33			$	5.12
Diluted:
Income from continuing operations		$	1.19			$	1.01			$	1.33			$	1.20			$	4.73
Income from discontinued operations		$	0.06			$	0.05			$	0.06			$	0.09			$	0.26
Net income (1)		$	1.26			$	1.06			$	1.39			$	1.29			$	4.99
AVERAGE SHARES OUTSTANDING
Basic			242,397				240,239				240,109				239,162				240,479
Diluted			248,311				245,890				245,696				245,056				246,798